SCHEMBL23660941

SCHEMBL23660941

Cn1ncc2ccc(C(C)(C)C)nc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.35
KDM4E B2RXH2 3/20 0.34
NPC1 O15118 3/20 0.34
MAPT P10636 3/20 0.34
RAB9A P51151 3/20 0.34
NOTUM Q6P988 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CDK2 P24941 1/20 0.33
GRN P28799 1/20 0.33
SORT1 Q99523 1/20 0.33
ERCC1 P07992 1/20 0.33
ERCC4 Q92889 1/20 0.33
MAPK1 P28482 2/20 0.33
KCNH2 Q12809 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HRH4 Q9H3N8 2/20 0.33
NPSR1 Q6W5P4 2/20 0.32
ERAP1 Q9NZ08 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26219713 0.79 KDM4E (0.31) KDM4ENPC1MAPTRAB9AATM
SCHEMBL7914443 0.74 RAB9A (0.41) TRPA1KDM4ENPC1MAPTRAB9A
SCHEMBL15525119 0.72 PDE2A (0.40) TRPA1KDM4ENPC1MAPTRAB9A
SCHEMBL29636867 0.72 PDE2A (0.40) TRPA1KDM4ENPC1MAPTRAB9A
SCHEMBL17673625 0.72 MAPT (0.37) TRPA1KDM4ENPC1MAPTRAB9A
SCHEMBL23346697 0.72 PI4KA (0.40) TRPA1NPC1MAPTRAB9ANOTUM
SCHEMBL30503614 0.72 MAPT (0.37) TRPA1KDM4ENPC1MAPTRAB9A
SCHEMBL25382823 0.72 NOTUM (0.39) TRPA1NPC1MAPTRAB9ANOTUM
SCHEMBL30168568 0.72 PI4KA (0.40) TRPA1NPC1MAPTRAB9ANOTUM
SCHEMBL15469665 0.71 DDB1 (0.37) KDM4EMAPTL3MBTL1MAPK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 WO disclosed
US-20210220365-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2021-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220365-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS GRIN2A, GRIN1, GRIN2B TRPA1 1344/4885KDM4E 2211/4885NPC1 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.